Navigation Links
Five-Year Data From Taxus II Clinical Trial Highlights Safety and Efficacy of Taxus(R) Stent Compared to Bare-Metal Stent
Date:9/4/2007

TAXUS(R) Stent shows no additional very late stent thrombosis

NATICK, Mass. and VIENNA, Austria, Sept. 4 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX) today announced five-year and final results from its TAXUS II clinical trial, demonstrating continued long-term safety and efficacy for the TAXUS(R) paclitaxel-eluting stent system. Among the findings, the TAXUS stent showed no additional stent thrombosis between years four and five, while the bare-metal control experienced one stent thrombosis during this same period. This marks the third consecutive year of TAXUS II follow-up with no stent thrombosis seen in the TAXUS stent patient group. The Company made the announcement at the annual European Society of Cardiology Congress in Vienna, Austria.

"Long-term results from TAXUS II reinforce the safety of paclitaxel- eluting stent technology and provide encouraging data regarding late and very late stent thrombosis out to five years," said Prof. Sigmund Silber, M.D., F.A.C.C., F.E.S.C., who presented the TAXUS II results at ESC 2007. "In this trial, the data revealed that the TAXUS paclitaxel-eluting stent maintained its efficacy benefits and had no thrombosis between years four and five while the bare-metal control had one additional thrombosis. These results warrant important consideration and possible further study if seen as an indication of longer term trends."

The efficacy advantage of the TAXUS Stent seen at six months was maintained through the five years following stent implantation, with the commercialized slow-release (SR) version of the TAXUS Stent reducing Target Lesion Revascularization (TLR) by 44 percent versus bare-metal stents (TAXUS SR 10.3%, BMS 18.4%, p=0.0003
'/>"/>

SOURCE Boston Scientific Corporation
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. New Study Suggests Better Patient Outcomes with CYPHER Sirolimus-Eluting Coronary Stent than with Taxus Stent in Real-World Clinical Settings
2. Positive Results for Second-Generation Taxus Liberte Coronary Stent System Highlighted in Journal of American College of Cardiology
3. SPIRIT Clinical Data Reaffirm Strength of Taxus and Promus Drug-Eluting Coronary Stent Systems
4. Taxus VI Clinical Trial Demonstrates Positive Long-Term Outcomes for Moderate-Release Paclitaxel-Eluting Stent at Four Years
5. Abbotts Xience V Everolimus Eluting Coronary Stent Superior to Taxus Stent in Spirit III U.S. Pivotal Clinical Trial
6. Genetic Analysis Systems Enter the Clinical Mainstream
7. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
8. Large Geographic Differences in EpiPen Prescriptions in the U.S., From the Journal of Allergy and Clinical Immunology
9. Sygnis Pharma AG announces date for presentation of clinical results
10. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
11. Clinical Data Suggest Decreased Bleeding Risk in People With Severe Hemophilia A While Maintaining Factor VIII Levels Above One Percent
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:AdEx Media, Inc. Signs Agreement with Medical Alarm Concepts 2AdEx Media, Inc. Signs Agreement with Medical Alarm Concepts 3Hand Surgeons Take Ethics into Their Own Hands 2Hand Surgeons Take Ethics into Their Own Hands 3Hand Surgeons Take Ethics into Their Own Hands 4Negative Pressure Wound Devices Draw FDA Notice, Advice 2New drugs faster from natural compounds 3A A UC San Diego breakthrough 13003 1New drugs faster from natural compounds 3A A UC San Diego breakthrough 13003 2New drugs faster from natural compounds 3A A UC San Diego breakthrough 13003 3New drugs faster from natural compounds 3A A UC San Diego breakthrough 13003 4Sex involved in plant defense 9248 1Sex involved in plant defense 9248 2Full Transcript of Pelosi Press Conference on Health Care Reform 51561 1Full Transcript of Pelosi Press Conference on Health Care Reform 51561 2Full Transcript of Pelosi Press Conference on Health Care Reform 51561 3Full Transcript of Pelosi Press Conference on Health Care Reform 51561 4Full Transcript of Pelosi Press Conference on Health Care Reform 51561 5Full Transcript of Pelosi Press Conference on Health Care Reform 51561 6Full Transcript of Pelosi Press Conference on Health Care Reform 51561 7Full Transcript of Pelosi Press Conference on Health Care Reform 51561 8Full Transcript of Pelosi Press Conference on Health Care Reform 51561 9Full Transcript of Pelosi Press Conference on Health Care Reform 51561 10Full Transcript of Pelosi Press Conference on Health Care Reform 51561 11Full Transcript of Pelosi Press Conference on Health Care Reform 51561 12Full Transcript of Pelosi Press Conference on Health Care Reform 51561 13Full Transcript of Pelosi Press Conference on Health Care Reform 51561 14Full Transcript of Pelosi Press Conference on Health Care Reform 51561 15Full Transcript of Pelosi Press Conference on Health Care Reform 51561 16Full Transcript of Pelosi Press Conference on Health Care Reform 51561 17Full Transcript of Pelosi Press Conference on Health Care Reform 51561 18